Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034

od Cheng, K.-C., Korfmacher, Walter A., White, Ronald E., Njoroge, F. George
Izdano 2007

Meeting Report: Metabolites in Safety Testing (MIST) Symposium—Safety Assessment of Human Metabolites: What’s REALLY Necessary to Ascertain Exposure Coverage in Safety Tests?

od Gao, Hongying, Jacobs, Abigail, White, Ronald E., Booth, Brian P., Obach, R. Scott
Izdano 2013

Interactions between Penicillin-Binding Proteins (PBPs) and Two Novel Classes of PBP Inhibitors, Arylalkylidene Rhodanines and Arylalkylidene Iminothiazolidin-4-ones

od Zervosen, Astrid, Lu, Wei-Ping, Chen, Zhouliang, White, Ronald E., Demuth, Thomas P., Frère, Jean-Marie
Izdano 2004

Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders

od Gurney, Mark E., Nugent, Richard A., Mo, Xuesheng, Sindac, Janice A., Hagen, Timothy J., Fox, David, O’Donnell, James M., Zhang, Chong, Xu, Ying, Zhang, Han-Ting, Groppi, Vincent E., Bailie, Marc, White, Ronald E., Romero, Donna L., Vellekoop, A. Samuel, Walker, Joel R., Surman, Matthew D., Zhu, Lei, Campbell, Robert F.
izdano v J Med Chem (2019)